Caribou Biosciences To Halt Two CAR-T Programs, Cut Workforce; Shares Plunge
(RTTNews) - Caribou Biosciences, Inc. (CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced plans to discontinue further development of its two allogeneic CAR-T cell therapy programs: vispa-cel for relapsed or refractory (r/r) B-cell non-Hodgkin lymp
